Pharmaceutical and Biotechnology Construction Sector Report – UK 2012-2016 Analysis

AMA Research are pleased to announce the publication of the 1st Edition of a new report: “Pharmaceutical and Biotechnology Construction Sector Report – UK 2012-2016 Analysis”. The report should be of particular interest to construction companies and their supply chains operating in the UK Life Sciences sector, and to suppliers of laboratory and allied products.

Key areas in the report:

Introduction to pharmaceutical, medical technology, medical and industrial biotechnology sectors – market size, key players and geographical areas of concentration.

Overview of main manufacturing and R&D facilities in UK.

Analysis of Government resource and capital funding for science and research.

Review of challenges facing the pharmaceutical sector.

Areas of particular interest:

Major contractors, consultants, architects and product suppliers involved in the pharmaceutical and biotechnology sectors.

Capital Expenditure levels in the pharmaceutical market.

Construction costs and issues in the design of pharmaceutical R&D/manufacturing facilities including legislation, regulatory requirements, containment and environmental issues, cleanroom and laboratory design.

Profiles of top pharmaceutical/biotechnology companies operating in the UK - revenue, capital expenditure, key manufacturing & R&D facilities in UK, future strategy, expansion plans, forward pipelines etc.

Government has also announced a forward pipeline of around £250m worth of capital projects in the pharmaceutical sector between 2012- 2017. Review of key projects together with announcements made by leading pharmaceutical companies and universities about future expansion and investment plans.

Detailed analysis of pharmaceutical clusters and centres of excellence in UK - the Oxford, Cambridge and London triangle houses the UK’s largest biomedical cluster, with over 350 pharma and biotech companies linked to universities and other organisations.

Leading pharmaceutical and biotechnology companies mentioned in the report include:

AstraZeneca, Abbott Laboratories, Abcam, ABS Laboratories, ACM Global Central Lab, Aesica Pharmaceuticals, Allergan, Bayer CropScience, Bells Healthcare, Calea (UK), Cancer Research Technology, Cantab Biopharmaceuticals, Carbogen Amcis, Cobra Biomanufacturing, Convergence Pharmaceuticals, Darchem, Eli Lilly, GlaxoSmithKline, Huntingdon Life Sciences, Intercytex, Isis Innovation, Life Technologies, Lonza Biologics, MedImmune, Merck & Co, Mundipharma International, Norbrook Pharmaceuticals, Novartis UK, NuPharm Laboratories, Oxygen Healthcare, Penn Pharma, Pfizer, Pharmaserve Northwest, PsiOxus Therapeutics, Reading Scientific Services, Recipharm, Redx Pharma, Renovo, Roche, Sanofi Aventis, Sareum, Teva Pharmaceutical Industries, TPP Global Development, UCB Pharma, Unilever.

Leading construction companies and consultants mentioned in the report include:

ABB Group, AECOM, AMEC, Ardmac, Bassaire, BDP, Bilfinger Berger, Cavendish Engineers, Clean Air Technologies, Clean Modules, Clean Room Construction, Cleanroom Design & Construction, Cleanroom Solutions, ClearSphere, Enbloc Cleanrooms, Foster Wheeler, Jacobs Engineering, Kier Group, Lend Lease, M+W UK, Mach-Aire, Merit Merrell, Nuvia, Precision Cleanrooms, SDC, Shepherd Construction, Sheppard Robson, Validair, Wilson Mason.

Key areas covered in the report include:

OVERALL ‘ PHARMACEUTICAL’ MARKET

Global Market - analysis of size by value 2008-14, historical trends and market characteristics.

UK Pharmaceutical Market – by value 2011 – overview/ mix of key sectors – Pharmaceutical, Medical Technology, Medical Biotechnology, Industrial Biotechnology.

Review of each key sector – key players, sector value, number of companies/staff, key locations, overview of development pipelines etc.

KEY PLAYERS

Summary overview of Top 30+ companies in Pharmaceuticals / Biotechnology - major companies and geographic location of facilities in UK – Manufacturing, R&D, Packaging, Logistics.

Geographic review – Oxford, Cambridge, London clusters. Other key regional areas - North West, Scotland, East England, South East etc – key players, future trends.

R&D in UK – budgets, funding sources. Government Resource and Capital Funding for Science & Research 2011 – 2015 Research Councils, HEFCE, EPSRC, MRC etc). Key funding recipients. Overview of R&D – key players, locations, development plans.

Top 20 companies in UK by R&D expenditure and by Drug Pipeline 2010/11.

Top players – market shares. Company profiles - Key Operating & Financial Summary Data (Incl: Capital and R&D Expenditure, Locations, Pipelines, Future Strategy etc) -GSK, Astra Zeneca, Novartis, Pfizer, Eli Lilley, Merck, Abbott Laboratories, Roche, Sanofi Aventis, Teva etc.

Review of smaller players – pharmaceuticals / biotechnology – Capex, R&D, locations, developments etc.

Universities – key links/collaborations with private sector, players (Top 20 with funding levels / sources). University/industry collaborations in the Pharmaceutical Sector 2010-11 – Partners, Funding, Project Areas etc.

Spin-out companies - between 2006 and 2010 university spin-out companies floated on the stock market were worth around £3.5bn and over the over the past decade, university bioscience departments alone have generated over 200 spin-out companies – overview of key players.

UK Science Parks - geographical spread, size / development plans, sectors, partners – Biocity, Liverpool, West of Scotland, York, Oxford, Cambridge etc.

CONSTRUCTION ACTIVITY

Capital Expenditure – 2001-2010 by Value – trends, background, drivers etc.

Science & Research Projects - Forward Construction Pipeline 2012-2017 – Schemes, Description, Funding Source, Status, Start/Completion Dates, Capex etc.

Other development announcements – plans – medium/long term, new opportunities etc.

Construction costs – laboratories, cleanrooms, key guidelines.

Leading Contractors – specialist cleanroom players (construction, supply and services).

Key consultants / contractors – Pharmaceuticals, Biotechnology - profiles of 20+ players – sector characteristics, major strengths and weaknesses, key sectors and capabilities.